RESPOND: Resuscitation in Paediatric Sepsis using Hydrocortisone and Vitamin C - A Randomized Controlled Multicentre Trial
Project Status
ActiveStart Date
End Date
Project locations
Background
Sepsis is a serious infection that can quickly become life‑threatening, especially in children, causing over 1 million deaths globally each year. Many children who survive may also face long‑term problems such as limb loss or brain-related disabilities. Despite ongoing efforts, improvements in sepsis treatment outcomes have been limited, and current treatment approaches rely mostly on antibiotics, fluids, and supportive care, with limited strong evidence for other therapies.
There is a need to explore new treatment strategies that can improve survival and recovery. One promising approach is the use of commonly available medicines like hydrocortisone (a steroid) and vitamin C, which may help reduce inflammation and support the body during severe infection. Since sepsis progresses rapidly and most deaths occur within the first 48 hours, early treatment is crucial. This study aims to test this treatment combination early in critically ill children to see if it can improve outcomes safely and effectively.
Aim
RESPOND aims to investigate if early intervention of Vitamin C and Hydrocortisone compared to hydrocortisone alone or standard care, impacts survival free of ICU in children presenting with septic shock.
Research methodology
RESPOND is a global, multi-centre, open-label, randomised controlled, parallel-group, three-arm trial recruiting across Australia, New Zealand, India and Brazil.
Current status
Recruitment is complete and data analysis is ongoing.